95 related articles for article (PubMed ID: 26864241)
1. Decreased exposure of atorvastatin in diabetic rats partly due to induction of hepatic Cyp3a and Oatp2.
Shu N; Hu M; Liu C; Zhang M; Ling Z; Zhang J; Xu P; Zhong Z; Chen Y; Liu L; Liu X
Xenobiotica; 2016 Oct; 46(10):875-81. PubMed ID: 26864241
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
Wang Z; Yang H; Xu J; Zhao K; Chen Y; Liang L; Li P; Chen N; Geng D; Zhang X; Liu X; Liu L
Drug Metab Dispos; 2019 Oct; 47(10):1066-1079. PubMed ID: 31399507
[TBL] [Abstract][Full Text] [Related]
3. The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp3a and SLCO1B1.
Shu N; Hu M; Ling Z; Liu P; Wang F; Xu P; Zhong Z; Sun B; Zhang M; Li F; Xie Q; Liu X; Liu L
Sci Rep; 2016 Sep; 6():33072. PubMed ID: 27624558
[TBL] [Abstract][Full Text] [Related]
4. Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.
Xu D; Li F; Zhang M; Zhang J; Liu C; Hu MY; Zhong ZY; Jia LL; Wang DW; Wu J; Liu L; Liu XD
Acta Pharmacol Sin; 2014 Sep; 35(9):1215-25. PubMed ID: 25152023
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of pravastatin on the pharmacokinetics of paroxetine in normal and diabetic rats.
Li F; Ling ZL; Wang ZJ; Zhong ZY; Shu N; Zhang M; Liu C; Liu L; Liu XD
Xenobiotica; 2017 Jan; 47(1):20-30. PubMed ID: 27145862
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of hepatic Pxr-Oatp2 pathway mediating decreased hepatic uptake of rosuvastatin in rats with high-fat diet-induced obesity.
Zhang F; Duan Y; Wei Y; Zhang J; Ma X; Tian H; Wang X; Saad AAA; Li B; Wu X
Life Sci; 2020 Sep; 257():118079. PubMed ID: 32668326
[TBL] [Abstract][Full Text] [Related]
7. The disposition of pravastatin in a rat model of streptozotocin-induced diabetes and organic anion transporting polypeptide 2 and multidrug resistance-associated protein 2 expression in the liver.
Hasegawa Y; Kishimoto S; Shibatani N; Inotsume N; Takeuchi Y; Fukushima S
Biol Pharm Bull; 2010; 33(1):153-6. PubMed ID: 20045956
[TBL] [Abstract][Full Text] [Related]
8. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study.
Maeda K; Ikeda Y; Fujita T; Yoshida K; Azuma Y; Haruyama Y; Yamane N; Kumagai Y; Sugiyama Y
Clin Pharmacol Ther; 2011 Oct; 90(4):575-81. PubMed ID: 21832990
[TBL] [Abstract][Full Text] [Related]
9. Drug transporters are altered in brain, liver and kidney of rats with chronic epilepsy induced by lithium-pilocarpine.
Guo Y; Jiang L
Neurol Res; 2010 Feb; 32(1):106-12. PubMed ID: 19570321
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection.
Chen GM; Hu N; Liu L; Xie SS; Wang P; Li J; Xie L; Wang GJ; Liu XD
Xenobiotica; 2011 Jun; 41(6):494-500. PubMed ID: 21506683
[TBL] [Abstract][Full Text] [Related]
11. Differential changes in the pharmacokinetics of statins in collagen-induced arthritis rats.
Lin CH; Hsu KW; Chen CH; Uang YS; Lin CJ
Biochem Pharmacol; 2017 Oct; 142():216-228. PubMed ID: 28636885
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
Lau YY; Okochi H; Huang Y; Benet LZ
Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
[TBL] [Abstract][Full Text] [Related]
13. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1.
Higgins JW; Ke AB; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2014 Nov; 42(11):1780-4. PubMed ID: 25106415
[TBL] [Abstract][Full Text] [Related]
14. Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats.
Sugatani J; Sadamitsu S; Kurosawa M; Ikushiro S; Sakaki T; Ikari A; Miwa M
Drug Metab Dispos; 2010 Oct; 38(10):1655-64. PubMed ID: 20587623
[TBL] [Abstract][Full Text] [Related]
15. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.
Hermann M; Bogsrud MP; Molden E; Asberg A; Mohebi BU; Ose L; Retterstøl K
Clin Pharmacol Ther; 2006 Jun; 79(6):532-9. PubMed ID: 16765141
[TBL] [Abstract][Full Text] [Related]
16. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
17. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Higgins JW; Bao JQ; Ke AB; Manro JR; Fallon JK; Smith PC; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2014 Jan; 42(1):182-92. PubMed ID: 24194513
[TBL] [Abstract][Full Text] [Related]
18. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
19. Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats.
Malekinejad H; Rokhsartalab-Azar S; Hassani-Dizaj S; Alizadeh-Fanalou S; Rezabakhsh A; Amniattalab A
Eur J Drug Metab Pharmacokinet; 2014 Dec; 39(4):311-20. PubMed ID: 24346850
[TBL] [Abstract][Full Text] [Related]
20. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
